神经丝蛋白与磷酸化tau/总tau比值在额颞叶痴呆谱系中的临床价值
在361例额颞叶痴呆(FTD)谱系患者和45名认知健康对照中,脑脊液神经丝轻链(NfL)和磷酸化tau/总tau比值(p/t-tau)可区分FTD与对照,但除FTD伴运动神经元病(FTD-MND)外不能区分临床亚型;两者均预测生存,且p/t-tau可特异性区分TDP与tau病理。
要点
- 除logopenic变异型原发性进行性失语(lvPPA,n=4)外,各临床诊断组NfL均高于对照,FTD-MND最高。
- 除lvPPA外,各临床组p/t-tau均低于对照,FTD-MND最低。
- NfL不能区分TDP与tau病理,p/t-tau区分TDP与tau病理的特异性76%、敏感性67%。
核心结论
- NfL和p/t-tau均可区分FTD与对照,但除FTD-MND外不能区分临床亚型。
- 两者均预测生存,是有前景的临床试验监测生物标志物。
- p/t-tau而非NfL可在体内特异性区分TDP与tau病理。
研究设计与样本
- 研究纳入361例FTD谱系患者:179例行为变异型FTD、17例FTD伴运动神经元病(FTD-MND)、36例语义变异型原发性进行性失语(PPA)、19例非流利变异型PPA、4例logopenic变异型PPA(lvPPA)、42例皮质基底节综合征、64例进行性核上性麻痹。
- 另纳入45名认知健康对照。
- 68例患者有明确的病理诊断:49例FTLD-TDP、18例FTLD-tau、1例FTLD-FUS。
- 检测脑脊液NfL和p/t-tau水平。
主要发现
- 除lvPPA(n=4)外,所有诊断组NfL均高于对照,行为变异型FTD、语义变异型PPA、非流利变异型PPA和皮质基底节综合征中升高程度相当,FTD-MND中最高。
- 除lvPPA外,所有临床组p/t-tau均低于对照,FTD-MND中最低。
- NfL不能区分TDP与tau病理,p/t-tau区分TDP与tau病理的特异性为76%、敏感性为67%。
- 高NfL和低p/t-tau均与不良生存相关(按三分位数的风险比:NfL为1.7,p/t-tau为0.7)。
关键数值与推荐
- p/t-tau区分TDP与tau病理:特异性76%,敏感性67%。
- 高NfL与不良生存相关,按三分位数的风险比为1.7。
- 低p/t-tau与不良生存相关,按三分位数的风险比为0.7。
- 证据分类:Class III证据,提示对于有认知问题的患者,脑脊液NfL和p/t-tau水平可区分有无FTD谱系疾病。
临床怎么用
- 作者认为NfL和p/t-tau是有前景的临床试验监测生物标志物。
- 作者指出p/t-tau而非NfL可在体内特异性区分TDP与tau病理。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the clinical value of neurofilament light chain (NfL) and the phospho-tau/total tau ratio (p/t-tau) across the entire frontotemporal dementia (FTD) spectrum in a large, well-defined cohort. METHODS: CSF NfL and p/t-tau levels were studied in 361 patients with FTD: 179 behavioral variant FTD, 17 FTD with motor neuron disease (FTD-MND), 36 semantic variant primary progressive aphasia (PPA), 19 nonfluent variant PPA, 4 logopenic variant PPA (lvPPA), 42 corticobasal syndrome, and 64 progressive supranuclear palsy. Forty-five cognitively healthy controls were also included. Definite pathology was known in 68 patients (49 frontotemporal lobar degeneration [FTLD]-TDP, 18 FTLD-tau, 1 FTLD-FUS). RESULTS: NfL was higher in all diagnoses, except lvPPA (n = 4), than in controls, equally elevated in behavioral variant FTD, semantic variant PPA, nonfluent variant PPA, and corticobasal syndrome, and highest in FTD-MND. The p/t-tau was lower in all clinical groups, except lvPPA, than in controls and lowest in FTD-MND. NfL did not discriminate between TDP and tau pathology, while the p/t-tau ratio had a good specificity (76%) and moderate sensitivity (67%). Both high NfL and low p/t-tau were associated with poor survival (hazard ratio on tertiles 1.7 for NfL, 0.7 for p/t-tau). CONCLUSION: NfL and p/t-tau similarly discriminated FTD from controls, but not between clinical subtypes, apart from FTD-MND. Both markers predicted survival and are promising monitoring biomarkers for clinical trials. Of note, p/t-tau, but not NfL, was specific to discriminate TDP from tau pathology in vivo. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for patients with cognitive issues, CSF NfL and p/t-tau levels discriminate between those with and without FTD spectrum disorders.
引用
- Meeter LHH, Vijverberg EG, Del Campo M, et al. Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. Neurology. 2018. PMID: 29514947. doi:10.1212/WNL.0000000000005261
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。